A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- RANDOMIZED · PARALLEL · BASIC SCIENCE · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 110
- Population
- ALL · 55 Years to 80 Years
- Duration
- 2014-02-01 to 2014-06-01
- Intervention
- LHA510 Ophthalmic Suspension; LHA510 Vehicle
- Comparator
- LHA510 Vehicle Part 1; LHA510 Vehicle Part 2
- Outcomes measured
- Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug,…; Number of Subjects Experiencing a Non-serious Adverse Event, Part I — From time of consent until 30 days after stopping…; Number of Subjects Experiencing a Non-serious Adverse Event, Part 2 — From time of consent until 30 days after stopping…; The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration [Mass / Volume] (Cmax), Par…; The Time to Reach the Maximum Concentration After Drug Administration [Time] (Tmax), Part 2 — Up to Day 15; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifia…; The Terminal Elimination Half-life [Time] (T1/2), Part 2 — Up to Day 15; Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 1 — Day 1: 0.25h, 0.5h, 1h, 2h, 4h,…; Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 1 — Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6…; Change From Baseline in Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 1 — Day 1: 0.25h, 0.5h, 1h, 2h,…; Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 2 — Day 1 and 7: 0.25h, 0.5h, 1h, 2h…; Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 2 — Day 1 and 7: 0.25h, 0.5h, 1h, 2h,…; Change From Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 2 — Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.